VRNA250117P30000
- 0.16
- 0.000.00%
Verona Pharma Newsroom
Roth MKM Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $68
Verona Pharma's Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Verona Pharma Is Maintained at Overweight by Wells Fargo
Verona Pharma Analyst Ratings
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $57
Wells Fargo Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $74
Wells Fargo Sticks to Their Buy Rating for Verona Pharma (VRNA)
BTIG Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $77
Truist Securities Raises Price Target on Verona Pharma to $57 From $44, Maintains Buy Rating
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Jefferies Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $50
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Wells Fargo Maintains Overweight on Verona Pharma, Raises Price Target to $64
Verona Pharma Is Maintained at Buy by Canaccord Genuity
A Quick Look at Today's Ratings for Verona Pharma(VRNA.US), With a Forecast Between $42 to $64
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
BTIG Remains a Buy on Verona Pharma (VRNA)
Verona Pharma Is Maintained at Buy by Truist Securities